< Back to latest news & events

News

HGF office closures in December 2023 and January 2024

December 2023

Please note that our offices will be closed for business in accordance with national holidays on the following dates. Please plan accordingly and provide us with your instructions in advance of any days we are closed. If you are sending instructions, always send a copy by email to docketing@hgf.com and ensure you receive a personal acknowledgement of receipt.

 

UK – HGF and IPO Office Closed Dates December 2023/January 2024

Monday 25 to Tuesday 26 December 2023 CLOSED
Monday 1 January 2024* CLOSED

*2 January 2024 – HGF Scottish Offices closed, UKIPO OPEN

Netherlands – HGF and IPO Office Closed Dates December 2023/January 2024

Monday 25 to Tuesday 26 December 2023 CLOSED
Monday 1 January 2024 CLOSED

Germany and Austria – HGF and IPO Office Closed Dates December 2023/January 2024

Monday 25 to Tuesday 26 December 2023 CLOSED
Monday 1 January 2024 CLOSED

Ireland – HGF and IPO Office Closed Dates December 2023/January 2024

Monday 25 to Tuesday 26 December 2023 CLOSED
Monday 1 January 2024 CLOSED

France – HGF and IPO Office Closed Dates December 2023/January 2024

Monday 25 December 2023 CLOSED
Monday 1 January 2024 CLOSED

Switzerland – HGF and IPO Office Closed Dates December 2023/January 2024

Monday 25 December 2023 CLOSED
Monday 1 January 2024 CLOSED
Intellectual Property Offices Closed Dates December 2023/ January 2024
EPO Monday 25 - Friday 29 December 2023. Monday 1 January 2024
EUIPO Monday 25 - Friday 29 December 2023. Monday 1-Tuesday 2 January 2024
WIPO Monday 25 December & Friday 29 December 2023. Monday 1 January 2024. (Open 26,27 & 28 December)

Latest updates

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Regulatory Exclusivity for
Medicinal Products in Europe

Video overview: New Medical Products 8 years of data exclusivity, followed by 2 years of market exclusivity. +1 year market exclusivity possible for a new indication showing significant clinical benefit. No exclusivity granted for new formulations or routes of …

Read article

Added Matter - Part 2

Video overview: Pre- and Post-Grant Amendments are governed by Articles 123(2) & 123(3) EPC respectively Before grant, amendments can broaden the claim scope as long as the resulting claim is …

Read article

Added Matter - Part 1

Video overview: What is Added Matter? Added matter occurs when an amendment introduces content that goes beyond what was originally disclosed in the application as filed (Article 123(2) EPC). EPO …

Read article

Patenting Polymorphs at the EPO

Video overview: Novelty and Inventive Step Prior art must necessarily lead to the claimed polymorph to be novelty destroying Watch out for inherent disclosures in prior art—methods may implicitly produce …

Read article

Antibodies

Video overview: EPO Requirements for Antibody Applications The EPO Guidelines (G-II, 6) provide a standardised framework for antibody-related patent issues. Antibodies can be defined by various aspects, including but not …

Read article

Description Amendment Requirements at EPO

Video overview: At the final stage of prosecution, the EPO increasingly insists each patent description must align with the allowed claims to improve clarity and eliminate inconsistencies. However, this strict …

Read article
See all updates